La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Evaxion Biotech Performance dei guadagni passati
Il passato criteri di controllo 0/6
Evaxion Biotech's earnings have been declining at an average annual rate of -7.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 155.2% per year.
Informazioni chiave
-7.3%
Tasso di crescita degli utili
9.0%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | 155.2% |
| Rendimento del capitale proprio | -1,213.5% |
| Margine netto | -5,469.4% |
| Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27
We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform
Jun 03Ripartizione dei ricavi e delle spese
Come Evaxion Biotech guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -15 | 9 | 11 |
| 31 Mar 24 | 0 | -15 | 9 | 11 |
| 31 Dec 23 | 0 | -22 | 10 | 12 |
| 30 Sep 23 | 0 | -24 | 11 | 14 |
| 30 Jun 23 | 0 | -25 | 10 | 15 |
| 31 Mar 23 | 0 | -24 | 9 | 16 |
| 31 Dec 22 | 0 | -23 | 8 | 17 |
| 30 Sep 22 | 0 | -25 | 7 | 19 |
| 30 Jun 22 | 0 | -24 | 7 | 19 |
| 31 Mar 22 | 0 | -26 | 7 | 20 |
| 31 Dec 21 | 0 | -25 | 6 | 20 |
| 30 Sep 21 | 0 | -20 | 6 | 16 |
| 30 Jun 21 | 0 | -19 | 7 | 15 |
| 31 Mar 21 | 0 | -16 | 6 | 12 |
| 31 Dec 20 | 0 | -15 | 6 | 11 |
| 30 Sep 20 | 0 | -14 | 5 | 11 |
| 31 Dec 19 | 0 | -11 | 3 | 8 |
Guadagni di qualità: EVAX is currently unprofitable.
Margine di profitto in crescita: EVAX is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: EVAX is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.
Accelerare la crescita: Unable to compare EVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: EVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Rendimento del capitale proprio
ROE elevato: EVAX has a negative Return on Equity (-1213.49%), as it is currently unprofitable.